Clinical Decision Support for Opioid Use Disorder in the Emergency Department
This study is looking at ways to improve care for people with opioid use disorder (OUD) in the emergency department (ED). Researchers are testing two versions of a computer tool called Clinical Decision Support (CDS). One version, CDSv1, helps ED doctors prescribe buprenorphine, a medication for OUD. The other version, CDSv2, adds information about a patient's social needs (like housing or food) to CDSv1. The goal is to see if CDSv2 helps more patients stick with their OUD treatment and follow-up care. The study aims to enroll 300 people. Success will be measured by how often doctors use these tools over 12 months. You may be able to join if you are an English-speaking patient aged 18 or older with OUD who receives medication treatment in the UCSF ED.
- Study design
- This is an interventional study comparing two versions of a clinical decision support tool. It will involve approximately 300 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study measures how often the tools are used over 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Using Clinical Decision Support to Provide Social Risk-Informed Care for Opioid Use Disorder in the Emergency Department
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Melanie F Molina, MD, MAS · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- CDSv1 clinician launch12 months
Percentage of ED clinicians who launch CDSv1 for patients with OUD
- CDSv1 encounter launch12 months
Percentage of eligible encounters (i.e., encounters including patients with OUD as defined by the EHR-derived phenotype) where CDSv1 was launched by clinician
- CDSv2 clinician launch12 months
Percentage of ED clinicians who launch CDSv2 for patients with OUD
- CDSv2 encounter launch12 months
Percentage of eligible encounters (i.e., encounters including patients with OUD as defined by the EHR-derived phenotype) where CDSv2 was launched by clinician
- CDSv1 adherence to OUD treatment recommendations12 months
For ED visits in which CDSv1 is launched, investigators will assess the percentage of times either buprenorphine, methadone, or naltrexone was prescribed by an ED clinician
- CDSv2 adherence to OUD treatment recommendations12 months
For ED visits in which CDSv2 is launched, investigators will assess the percentage of times either buprenorphine, methadone, or naltrexone was prescribed by an ED clinician
- CDSv2 adherence to social care recommendations12 months
For ED visits in which CDSv2 is launched, investigators will assess the percentage of times social care recommendations (to be determined, based on results from Aim 2) were followed by ED clinicians
- CDSv1 acceptabilityDuring first 6 months of CDSv1 deployment
Acceptability of Intervention Measure 4-item survey to assess clinician acceptability of CDSv1. Response scales range from "1 = Completely disagree" to "5 = Completely agree", with higher scores indicating greater success.
- CDSv1 appropriatenessDuring first 6 months of CDSv1 deployment
Intervention Appropriateness Measure 4-item survey to assess clinician perception of CDSv1 appropriateness. Response scales range from "1 = Completely disagree" to "5 = Completely agree", with higher scores indicating greater success.
- CDSv2 acceptabilityDuring first 6 months of CDSv2 deployment
Acceptability of Intervention Measure 4-item survey to assess clinician acceptability of CDSv2. Response scales range from "1 = Completely disagree" to "5 = Completely agree", with higher scores indicating greater success.
- CDSv2 appropriatenessDuring first 6 months of CDSv2 deployment
Intervention Appropriateness Measure 4-item survey to assess clinician perception of CDSv2 appropriateness. Response scales range from "1 = Completely disagree" to "5 = Completely agree", with higher scores indicating greater success.
- Patient recruitment CDSv112 months
Number of patients who receive OUD medication as a result of CDSv1 who are enrolled for primary outcome ascertainment
- Patient recruitment CDSv212 months
Number of patients who receive OUD medication as a result of CDSv2 who are enrolled for primary outcome ascertainment
- ED clinicians' perceptions of CDSv1Within first 8 months of CDSv1 deployment
Themes emerging from semi-structured qualitative interviews exploring clinician perceptions of CDSv1
- ED patients' perceptions of CDSv1Within first 8 months of CDSv1 deployment
Themes emerging from semi-structured qualitative interviews exploring patient perceptions of receiving treatment from CDSv1
- ED clinicians' perceptions of CDSv2Within first 8 months of CDSv2 deployment
Themes emerging from semi-structured qualitative interviews exploring clinician perceptions of CDSv2
- ED patients' perceptions of CDSv2Within first 8 months of CDSv2 deployment
Themes emerging from semi-structured qualitative interviews exploring patient perceptions of receiving social risk-informed treatment from CDSv2
- Feasibility of primary endpoint collection for CDSv113 months
Percentage of participants for whom data on OUD medication adherence and follow up are successfully collected at 30 days for CDSv1
- Feasibility of primary endpoint collection for CDSv213 months
Percentage of participants for whom data on OUD medication adherence and follow up are successfully collected at 30 days for CDSv2